Nasopharyngeal Cancer
Conditions
Keywords
gemcitabine, carboplatin, cisplatin, erlotinib, tarceva, nasopharyngeal
Brief summary
Cisplatin or Carboplatin will be given on day 1 every 21 days for 6 cycles; Gemcitabine will be given on day 1 and day 8 every 21 days for 6 cycles. Those patients that do not progress on GC after 6 cycles of chemotherapy will be started on erlotinib daily until disease progression. A cycle of erlotinib will be 28 days. Patients who progress on GC will be offered erlotinib as well,in order to evaluate its activity as a single-agent in the second-line setting. Patients previously treated with GC have reported a progression-free survival (PFS) of 9 months. We would anticipate an extension of PFS to 12 months in patients treated with GC followed by maintenance erlotinib. Furthermore, we hypothesize that patients who achieved benefit from GC therapy would have further response when treated with maintenance erlotinib, such that this strategy may increase the likelihood of attaining long-term survival.
Interventions
DRUGGemcitabine
1000mg/m\^2 intravenous (IV) day 1 and day 8
Area under curve (AUC)=5 (Carboplatin) or 70mg/m\^2 (Cisplatin) intravenous (IV) day 1
DRUGerlotinib
150mg daily (post GC therapy)
Sponsors
Hoffmann-La Roche
University Health Network, Toronto
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically confirmed World Health Organization (WHO) type I (keratinizing squamous cell carcinoma) or WHO type II a or b (differentiated non-keratinizing carcinoma or undifferentiated carcinoma) NPC. * Presence of clinically and/or radiologically documented disease. At least one site of disease must be unidimensionally measurable as follows: * X-ray, physical exam \> 20 mm * Spiral CT scan \> 10 mm * Non-spiral CT scan \> 20 mm * Investigations including chest x-ray or CT scan of chest, CT or MRI of head and neck (for patients with locally advanced or locally recurrent disease) and other scans as necessary to document all sites of study disease have been performed within 28 days prior to randomization. (Exceptions will be made only for patients who have negative examinations within 35 days prior to registration; exceptions for bone scans will be made for negative examinations within 60 days prior to registration.) * Age \> 18 years. * ECOG performance status of 0,1 or 2 (see Appendix II). * Patients must have a life expectancy of at least 12 weeks. * Previous Therapy: * Chemotherapy: Advanced Disease: Patients may not have had prior therapy for recurrent or metastatic disease. * Curative Therapy: Patients may have had prior chemotherapy (including cisplatin/ carboplatin based regimens) in the neoadjuvant, concurrent and adjuvant setting for locally advanced nasopharyngeal carcinoma provided that 4 weeks have elapsed since treatment and any residual treatment related neuropathy or ototoxicity is \< grade 1 for cisplatin dosing on this trial. Patient with neuropathy or ototoxicity \> grade 2 will be dosed with carboplatin if otherwise eligible for this trial. * Radiation: Patients may have received prior radiotherapy provided that the last fraction was given at least 4 weeks prior to registration and all toxicities have resolved. If radiotherapy was delivered to the only site of measurable disease, then progression must have been documented in that site after completion of radiotherapy and prior to registration. * Previous Surgery: Previous major surgery is permitted provided that it has been at least 21 days prior to patient registration and that wound healing has occurred. * Laboratory Requirements (must be done within 7 days prior to registration) * Hematology: * granulocytes (AGC) \> 1.5 x 109/L * platelets \> 100 x 109/L * Chemistry: * AST \< 2.5 x UNL * ALT \< 2.5 x UNL * Creatinine clearance(\*) : CrCl \> 60mls/min for cisplatin or CrCl between 30 - 59ml/min for Carboplatin (\*) calculated * Patient consent must be obtained according to local Institutional and/or University Human Experimentation Committee requirements. The patient must sign the consent form prior to randomization or registration. * Patients must be accessible for treatment and follow up. * Normal serum calcium
Exclusion criteria
* Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for \> 5 years. * Patients with non-measurable disease only. (Please note that bone metastases are considered non-measurable). * Pregnant or lactating women. However, if the patient is of childbearing potential, a urine β-HCG must be proved negative within 7 days prior to registration. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. * Patients with known brain metastases. (A head CT is not necessary to rule out brain metastases, unless there is clinical suspicion of CNS involvement). * Serious illness or medical condition, which would not permit the patient to be managed according to the protocol including, but not limited to: * History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent or limit compliance with study requirements; * Active uncontrolled infection; * Symptomatic congestive heart failure, unstable angina, cardiac arrhythmia. * Prior anti-EGFR monoclonal antibody or tyrosine kinase inhibitors. * Any inflammatory changes of the surface of the eye. * Hypersensitivity to erlotinib (Tarceva) or to any of the excipients * Concomitant requirement for medications classified as CYP3A4 inducer or inhibitor. Inhibitors of CYP3A4 are prohibited beginning at least seven (7) days prior to the administration of the first dose of study medication and for the duration of the study. Inducers of CYP3A4 are prohibited beginning at least fourteen (14) days prior to the administration of the first dose of study medication and for the duration of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival. | From the on-study date until the date of first documented progression or date of death from any cause any cause until all participants have progressed or died. | From randomization to the first documented disease progression or death from any cause, whichever came first, assessed until all participants randomized to the study have progressed for died. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With the Responses Outlined | Measured every 2 cycles until the participant is off treatment. | Complete Response (CR): disappearance of all clinical and radiological evidence of tumour. Partial Response (PR): at least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Progressive Disease (PD): at least a 20% increase in the sum of LD of measured lesions taking as references the smallest sum LD recorded since the treatment started. Appearance of new lesions will also constitute progressive disease. |
Countries
Canada
Participant flow
Recruitment details
Study was activated on 14-June-2006. Patients with nasopharyngeal carcinoma meeting the eligibility criteria specified in the protocol were enrolled.
Participants by arm
| Arm | Count |
|---|---|
| GEMCITABINE AND CISPLATIN/CARBOPLATIN (GC) PLUS ERLOTINIB patients with recurrent and/or metastatic NPC will be treated with 6 cycles of GC followed by maintenance erlotinib (150mg by mouth daily) for 6 cycles. | 20 |
| Total | 20 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Physician Decision | 1 |
Baseline characteristics
| Characteristic | GEMCITABINE AND CISPLATIN/CARBOPLATIN (GC) PLUS ERLOTINIB |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 4 Participants |
| Age, Categorical Between 18 and 65 years | 16 Participants |
| Performance Status 0 | 10 Participants |
| Performance Status 1 | 10 Participants |
| Region of Enrollment Canada | 20 participants |
| Sex: Female, Male Female | 7 Participants |
| Sex: Female, Male Male | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 20 / 20 |
| serious Total, serious adverse events | 7 / 20 |
Outcome results
Primary
Progression Free Survival.
From randomization to the first documented disease progression or death from any cause, whichever came first, assessed until all participants randomized to the study have progressed for died.
Time frame: From the on-study date until the date of first documented progression or date of death from any cause any cause until all participants have progressed or died.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| GEMCITABINE AND CISPLATIN/CARBOPLATIN (GC) PLUS ERLOTINIB | Progression Free Survival. | 6.3 Months |
Secondary
Number of Participants With the Responses Outlined
Complete Response (CR): disappearance of all clinical and radiological evidence of tumour. Partial Response (PR): at least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Progressive Disease (PD): at least a 20% increase in the sum of LD of measured lesions taking as references the smallest sum LD recorded since the treatment started. Appearance of new lesions will also constitute progressive disease.
Time frame: Measured every 2 cycles until the participant is off treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| GEMCITABINE AND CISPLATIN/CARBOPLATIN (GC) PLUS ERLOTINIB | Number of Participants With the Responses Outlined | Complete Response | 0 Participants |
| GEMCITABINE AND CISPLATIN/CARBOPLATIN (GC) PLUS ERLOTINIB | Number of Participants With the Responses Outlined | Partial Response | 7 Participants |
| GEMCITABINE AND CISPLATIN/CARBOPLATIN (GC) PLUS ERLOTINIB | Number of Participants With the Responses Outlined | Stable Disease | 11 Participants |
| GEMCITABINE AND CISPLATIN/CARBOPLATIN (GC) PLUS ERLOTINIB | Number of Participants With the Responses Outlined | Progressive Disease | 1 Participants |
| GEMCITABINE AND CISPLATIN/CARBOPLATIN (GC) PLUS ERLOTINIB | Number of Participants With the Responses Outlined | Inevaluable | 1 Participants |